Navigation Links
Tarceva Found To Benefit Older Lung Cancer Patients

A new drug has shown promise in the clinical trials involving lung cancer patients and it has even been proposed to evaluate the drug as a frontline therapy for those with lung cancer. One of the significant problems // faced in the treatment regime in the elderly patients is the tolerability and side effects of the drugs currently used.

The tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer according to researchers from Boston.

Erlotinib is designed to specifically and potently block an overactive growth-signaling molecule (EGFR) in cancer cells. The drug has also showed encouraging activity in patients with failed chemotherapy attempts. The present study is the first reported in the assessment of erlotinib in patients who have not received chemotherapy.

The study involved 80 patients with either Stage IIIB or IV presentation who were subjected to erlotinib treatment for 2 years. Almost 60 percent of the patients experienced either a partial response or had stable disease, though none of them had a complete response. The median survival was 46 weeks, and the median duration of partial response and stable disease was 65 weeks and 24 weeks, respectively.

In addition, all patients were evaluated for survival and toxicity; 69 were evaluated for best response. Ten patients discontinued from the study because of toxicity, and there was one treatment-related death from pneumonitis. Rashes (74%) and diarrhea (60 %) were the most common observed side effects.

Following success of the Phase II trials, the Phase III trial would be directed to comparing erlotinib with single-agent navelbine in the above mentioned population shortly.

In conclusion, erlotinib has been found to display encouraging activity and improve median survival in lung cancer patient s. It is also well tolerated in patients over 70 years, a significant finding.

However, further research might be necessary before the drug can be used in the initial treatment of advanced lung cancer rather than approach involving conventional chemotherapy.
'"/>




Related medicine news :

1. Drug Tarceva for End-stage Lung cancer
2. Roche Calls For Re-Examination Of Tarceva Data By EU Authorities
3. Fluoride Found Effective in Osteoporosis
4. Implantable Contact Lens Found Safe and Effective
5. Cancer hazard Found With Animal-Based Nutrients
6. Processed Meat, Diabetes connection Found
7. Night Time Aspirin Regimen Found to Reduce Blood Pressure
8. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
9. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
10. Preventive Therapies Found to be More Effective in Managing Migraines
11. Common Cold Found to Fight Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology: